Bone mineral density increase and safety of TSE-424 [bazedoxifene] compared to placebo in osteoporotic postmenopausal women

Trial Profile

Bone mineral density increase and safety of TSE-424 [bazedoxifene] compared to placebo in osteoporotic postmenopausal women

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2011

At a glance

  • Drugs Bazedoxifene (Primary)
  • Indications Menopause; Postmenopausal osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2008 Efficacy and safety results were presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research.
    • 17 Dec 2007 Status changed from in progress to completed.
    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top